Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-CD137 (4-1BB) (BMS-663513), BMS-663513
Anti-CD137 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 0.1 mg/kg every 3 weeks |
| Arm 2 | ACTIVE_COMPARATOR | 1 mg/kg every 3 weeks |
| Arm 3 | ACTIVE_COMPARATOR | 1 mg/kg every 6 weeks |
| Arm 4 | ACTIVE_COMPARATOR | 5 mg/kg every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Anti-CD137 (4-1BB) (BMS-663513) | DRUG | IV solution, IV, until PD or toxicity |
Inclusion Criteria: * Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvan...
Top 20 of 52 competitors
Anti-CD137 was studied as a treatment for melanoma, specifically as a second-line monotherapy in a Phase 2 trial. It was developed by Bristol-Myers Squibb Company for patients with melanoma. The program is investigational and has not been approved for any indication.
Anti-CD137 targets CD137, also known as 4-1BB, a costimulatory receptor on immune cells. By binding this target, the agent is designed to stimulate immune responses against tumor cells. This mechanism was explored in melanoma as a potential immunotherapy approach.
Anti-CD137 is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored the clinical trial evaluating this agent in melanoma. Bristol-Myers Squibb is the sole developer listed for this asset.
Anti-CD137 is in Phase 2 development. It has completed one Phase 2 trial in melanoma, and no active trials are currently listed. The drug remains investigational and has not received FDA approval for any indication.
Anti-CD137 has been evaluated in one completed Phase 2 trial, NCT00612664, titled "Phase II, 2nd Line Melanoma - RAND Monotherapy." The trial enrolled 158 patients with melanoma across the United States, Canada, Denmark, France, Germany, and Italy. It was randomized and active-controlled.
Yes, anti-CD137 is also known as anti-CD137 (4-1BB) (BMS-663513). These names refer to the same investigational agent developed by Bristol-Myers Squibb. The alternative names reflect its target, CD137 or 4-1BB, and its internal compound designation, BMS-663513.